Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison

Clinical Therapeutics

Volumn 38, Issue 2, 2016, Pages 404-412

  Swallow, Elyse ^a   Song, Jinlin ^a   Yuan, Yong ^b   Kalsekar, Anupama ^b   Kelley, Caroline ^a   Peeples, Miranda ^a   Mu, Fan ^a   Ackerman, Peter ^b   Signorovitch, James ^a  

^a ANALYSIS GROUP   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

daclatasvir; hepatitis C; HIV; matching adjusted indirect comparison; ribavirin; sofosbuvir

Indexed keywords

ABACAVIR; DACLATASVIR; EMTRICITABINE; HEMOGLOBIN; INTEGRASE INHIBITOR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TENOFOVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; PHASE 3 CLINICAL TRIAL (TOPIC);

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COINFECTION; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMIDAZOLES; RIBAVIRIN; SOFOSBUVIR;

EID: 84961664700     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.12.017     Document Type: Article

References (23)

1. N. Bräu Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin Semin Liver Dis 25 2005 33 51
2. Panel on Antiretroviral Guidelines for Adults Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2009 Department of Health and Human Services Washington, DC 1 161
3. V. Martel Laferrière, and D.T. Dieterich Treating HCV in HIV 2013: on the cusp of change Liver Int 34 2014 53 59
4. J.-M. Molina, C. Orkin, D.M. Iser, and et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study Lancet 385 9973 2015 1098 1106
5. M.S. Sulkowski, S. Naggie, J. Lalezari, and et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection JAMA 312 2014 353 361
6. European Medicines Agency. EPAR summary for the public: Daklinza (daclatasvir). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/003768/WC500172850.pdf. Accessed January 7, 2016.
7. Bristol-Myers Squibb. Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the Treatment of Hepatitis C Genotype 3. http://news.bms.com/press-release/bristol-myers-squibb-announces-acceptance-new-drug-application-investigational-daclata. Accessed March 12, 2015.
8. D.L. Wyles, P.J. Ruane, M.S. Sulkowski, and et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 N Engl J Med 373 2015 714 725
9. Eley T, You X, Wang R, et al. Daclatasvir: Overview of Drug-Drug Interactions With Antiretroviral Agents and Other Common Concomitant Drugs HIV DART, Miami, FL, December 9-12, 2014. http://natap.org/2014/HCV/121614-01.htm. Accessed January 7, 2016.
10. American Associaton for the Study of Liver Diseases/Infectious Diseases Society of American/International Antiviral Society-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view. Accessed June 3, 2015.
11. European Association for the Study of the Liver EASL Recommendations on Treatment of Hepatitis C 2015 J Hepatol 63 2015 199 236
12. U.S. Food and Drug Administration. Sovaldi (sofosbuvir). http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204671s000lbl.pdf. August 2015. Updated September 10, 2015. Accessed January 7, 2016.
13. European Medicines Agency. EPAR summary for the public: Sofosbuvir (sovaldi). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/002798/WC500160599.pdf. Accessed January 7, 2016.
14. A. Liberati, D.G. Altman, J. Tetzlaff, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
15. J.E. Signorovitch, E.Q. Wu, A.P. Yu, and et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept Pharmacoeconomics 28 2010 935 945
16. D.L. Thomas The challenge of hepatitis C in the HIV-infected person Annu Rev Med 59 2008 473 485
17. L.I. Backus, D.B. Boothroyd, B.R. Phillips, and et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C Clin Gastroenterol Hepatol 9 509-516 2011 509 516 e1
18. D. Larrey, M.P. Ripault, and G.P. Pageaux Patient adherence issues in the treatment of hepatitis C Patient Prefer Adherence 8 2014 763 773
19. L. Fusfeld, J. Aggarwal, C. Dougher, and et al. Assessment of motivating factors associated with the initiation and completion of treatment for chronic hepatitis C virus (HCV) infection BMC Infect Dis 13 2013 234
20. N. Anwar, and K.E. Sherman HCV treatment of special populations: HIV coinfected, liver transplant, and renal failure Clin Liver Dis 4 2014 80 83
21. Strategies for Management of Antiretroviral Therapy (SMART) Study Group W.M. El-Sadr, J. Lundgren, and et al. CD4+ count-guided interruption of antiretroviral treatment N Engl J Med 355 2006 2283 2296
22. Hull M, Cescon A, Raboud J, et al. Switching from first antiretroviral therapy regimen while virologically suppressed is associated with increased risk of subsequent virologic failure. 20th International AIDS Conference. Melbourne, July 20-25, 2014. Abstract TUAB0103.
23. J. Signorovitch, R. Ayyagari, D. Cheng, and et al. Matching-adjusted indirect comparisons: A simulation study of statistical performance Value Health 3 2013 A48